{{Drugbox
| Watchedfields = changed
| verifiedrevid = 453369718
| IUPAC_name = 4-(3-{Ethyl[3-(propane-1-sulfinyl)propyl]amino}-2-hydroxypropoxy)benzonitrile
| image = almokalant.svg
| alt =

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 123955-10-2
| ATCvet =  
| ATC_prefix = None
| ATC_suffix =   
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = I9NG89L275
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 362103
|  PubChem = 3033962
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2298526
|  smiles = O=S(CCC)CCCN(CC)CC(O)COc1ccc(C#N)cc1
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H28N2O3S/c1-3-11-24(22)12-5-10-20(4-2)14-17(21)15-23-18-8-6-16(13-19)7-9-18/h6-9,17,21H,3-5,10-12,14-15H2,1-2H3
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZMHOBBKJBYLXFR-UHFFFAOYSA-N

<!--Chemical data-->
| C=18 | H=28 | N=2 | O=3 | S=1 
| molecular_weight = 352.5 g/mol
}}

'''Almokalant''' is a [[drug]] used to treat [[Antiarrhythmic agent|arrhythmia]].<ref>{{cite journal |vauthors=Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI | title =  Torsades de pointes with Almokalant, a new class III antiarrhythmic drug | journal = American Heart Journal | year = 1993 | volume = 126 | issue = 4 | pages = 1008–1011 | doi=10.1016/0002-8703(93)90726-p}}</ref>  It is a [[potassium channel blocker]]. It has been found to have [[teratogenic]] effects in rats.<ref>{{Cite journal|title = Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species|journal = Reproductive Toxicology (Elmsford, N.Y.)|date = 1999-04-01|issn = 0890-6238|pmid = 10213516|pages = 93–101|volume = 13|issue = 2|first = K.|last = Wellfelt|first2 = A. C.|last2 = Sköld|first3 = A.|last3 = Wallin|first4 = B. R.|last4 = Danielsson}}</ref>

==References==
{{Reflist}}

[[Category:Potassium channel blockers]]
[[Category:Nitriles]]
[[Category:Sulfoxides]]


{{cardiovascular-drug-stub}}